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Background: Recently, slow release tablets have been developed to prolong energy release throughout the day.
The efficacy of the delivery of slow-release caffeine alone is fairly well documented; however, an assessment of
safety and tolerability of prolonged use of slow-release energy supplements is lacking. Therefore the objective of
this study was to investigate the effect of daily ingestion of a slow-release energy supplement for 28 days on blood
chemistry and resting cardiovascular measures in healthy men and women.
Methods: Forty healthy individuals (20 males, 20 females; age: 22.73 ± 3.06 years; height: 171.68 ± 10.45 cm; mass:
74.49 ± 15.51 kg; BMI: 25.08 ± 3.66 (kg • m2) -1) participated in this randomized, double-blind, placebo controlled
study. Following a 12-hour fast, participants reported for pre-testing. Testing consisted of resting heart rate (RHR)
and blood pressure (BP) measures, followed by assessment of metabolic blood chemistry, blood lipids and complete
cell counts. Participants then supplemented with either Energize™ (SUPP) or placebo (PL) for 28 days. Post-testing
occurred 24-hours after ingestion of the final dose and consisted of the same protocol at the same time of day
as pre-testing.
Results: No significant changes in outcome measures were observed. A significant difference between groups was
observed for plasma glucose concentrations; however, follow-up testing revealed that pre- to post-supplementation
changes were not significant for either SUPP or PL. All variables remained within normal adult reference ranges.
No adverse events were reported.
Conclusions: These findings indicate that 28 consecutive days ingestion of a slow release energy supplement
containing caffeine in caffeine users is both safe and tolerable.
Keywords: Energy supplement, Slow-release, Caffeine, Health, Safety, Comprehensive blood chemistry, Lipid profile,
Complete blood counts, Resting heart rate, Blood pressureBackground
Caffeine is the most frequently consumed pharmacologic-
ally active substance in the world [1,2], where approxi-
mately 80 percent of the adult population consumes
between 200–250 mg of caffeine on a daily basis [3]. Mod-
erate doses of caffeine can lead to an increase in both
physical and mental task performance [4-10], making* Correspondence: jay.hoffman@ucf.edu
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and sub-optimal arousal. Caffeine’s effect is likely attribut-
able to its function as a mild central nervous system
(CNS) stimulant [11], whereby it competitively binds to
adenosine receptors, leading to a suppression of its inhibi-
tory effect on CNS activity [12]. Accordingly, caffeine is
the main physiologically active ingredient in many com-
mercially available energy supplements [13]. Nevertheless,
caffeine and caffeine-containing energy supplements alike,
typically induce only 90–120 minutes of increased alertnesstd. This is an Open Access article distributed under the terms of the Creative
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following their metabolism [16,17]. Additionally, the
amounts of these ingredients are often undisclosed
and unregulated [18]. As a consequence, repeat adminis-
tration of such energy supplements may lead to more aver-
sive effects and dysphoric reactions over time [3]. Of
particular concern are the effects of prolonged use on
resting cardiovascular parameters, as well as on hepatic
and renal function.
Recently, slow release tablets have been developed to
prolong energy release throughout the day [14,19]. Phar-
macokinetic studies have demonstrated that these tablets
are able to provide a steady release of caffeine and other
compounds over a longer period of time [20], likely elim-
inating the need for repeat administration and possibly
reducing any potential adverse effects associated with re-
peated use [21]. Therefore, the use of these tablets to de-
liver an energy supplement may be beneficial for workers
involved in sustained operations that demand peak cogni-
tive and physical performance, and provide a safer alterna-
tive to repeated dosing.
The efficacy of the delivery of slow-release caffeine
alone is fairly well documented [3,21-23]. However, an
assessment of safety and tolerability of prolonged use of
slow-release energy supplements is lacking. Therefore, the
purpose of this study was to investigate the effects of
28-days ingestion of a commercially available slow-release
energy supplement on blood lipid profiles, comprehensive
blood chemistry, and complete blood counts in young,
healthy men and women.
Methods
Participants
Forty healthy individuals (20 men, 20 women; age: 22.73 ±
3.06 years; height: 171.68 ± 10.45 cm; mass: 74.49 ±
15.51 kg; BMI: 25.08 ± 3.66 (kg • m2) -1) who were regu-
lar consumers of caffeine volunteered to participate in
this randomized, double-blind, placebo controlled study.
Anthropometric data by group is presented in Table 1.
The research protocol was approved by the New England
Institutional Review Board. Following an explanation of
all risks and benefits associated with the experimental
protocol, each participant gave his or her informed con-
sent to participate in this study. For inclusion in theTable 1 Participant anthropometric characteristics
Variable SUPP (n = 20) PL (n = 20)
(10 men, 10 women) (10 men, 10 women)
Age (years) 22.95 ± 3.05 22.5 ± 3.13
Height (cm) 172.83 ± 8.84 170.54 ± 11.97
Mass (kg) 73.77 ± 12.65 75.21 ± 18.23
BMI (kg • m2)-1 24.62 ± 3.35 25.53 ± 3.97
Data presented as mean ± SD.study, participants had to be regular caffeine consumers
(between 60–180 mg per day). Participants were excluded
if they had any history of cardiovascular disease, meta-
bolic, renal, hepatic, or musculoskeletal disorders or were
taking any other medication (other than oral contracep-
tives) as determined by a confidential medical history
questionnaire. Participants were also excluded as a result
of any intolerance or known allergy to the supplement in-
gredients. While enrolled in the study, participants were
permitted to maintain their normal caffeine intake.
Experimental design
The experimental design is depicted in Figure 1. Follow-
ing the initial screening visit, participants reported to the
Human Performance Laboratory (HPL) on 22 separate oc-
casions. Testing was conducted at pre- (visit 1) and post-
(visit 22) supplementation only. Testing sessions were
separated by 28 days. For each testing session, partici-
pants were required to report to the HPL following a
12-hour fast. Resting heart rate (RHR) and blood pressure
(BP) were recorded, followed by a venous blood draw.
Upon completion of pre-testing during visit 1, participants
were required to consume the first dosage of Energize™
(iSatori, Golden, CO, USA) (SUPP) or placebo (PL) wit-
nessed by one of the research personnel. Participants then
continued supplementation for an additional 27 days.
Supplement and placebo were provided by the sponsor
in coded bottles. Each bottle contained 28-days’ worth
of supplement or placebo. Subject numbers were assigned
to each code chronologically following obtainment of con-
sent. Subject numbers were permanently marked on their
respective bottles, and each daily serving for each partici-
pant was taken from the same bottle until completion of
the study. Participants were required to report to the HPL
on all weekdays (20 total visits) to receive either SUPP or
PL. On weekends, participants were provided 2 dosages of
SUPP or PL to consume on each weekend day. Weekend
supplementation was provided in zip lock bags with clear
instructions on how to take the supplement. All partici-
pants were required to consume the supplement before
4 pm each day to avoid disturbance of sleep cycles and re-
turn the bags the following Monday to demonstrate ad-
herence. Post-testing (visit 22) occurred the day following
ingestion of the last dosage. Following a 12-hour fast, par-
ticipants completed the same testing protocol as at pre-
testing, at the same time of day. Recent reviews suggest
that a daily caffeine dosage of 400 mg • d−1 is not associ-
ated with risk of toxicity, changes in behavior or adverse
cardiovascular effects [2,24]. Since participants in the
present study reported an average daily consumption of
60–180 mg of caffeine, the addition of the supplement
placed average daily consumption below this threshold.
As a result, changes in hematological and/or cardiovascu-
lar variables are likely related to the time-release nature of
Figure 1 Experimental Design Schematic.
Table 2 Supplement Ingredients (per serving size)
Ingredients Amount
Thiamine (vitamin B1) (as thiamine hydrochloride) 5.2 mg
Vitamin B6 (as pyridoxine hydrochloride) 25 mg
Folate (as folic acid) 200 μg
Vitamin B12 (as cyanocobalamin) 3 μg
Magnesium (as magnesium oxide) 150 mg
Proprietary Energizer Formula: 1600 mg
L-Tyrosine
Glucuronolactone
Natural Caffeine (coffee arabica) (seed)-sustained release 194 mg
Theobromine (theobroma cacao) (seed)
Rhodiola Rosea Extract (root) (standardized to contain
3% rosavins & 1% salidroside)
Korean Ginseng Powder (root)
Octacosonal (from sugar cane polycosanol)
mg =milligrams; μg =micrograms.
Wells et al. Journal of the International Society of Sports Nutrition 2014, 11:59 Page 3 of 7
http://www.jissn.com/content/11/1/59the supplement. All participants were asked to report any
adverse effects they felt were directly attributable to inges-
tion of the supplement at post-testing.
Testing sessions
During visits 1 and 22, anthropometrics, RHR and BP were
assessed. Upon arrival to the HPL, body mass (± 0.1 kg)
and height (± 0.1 cm) were measured using a Health-O-
Meter professional scale (Patient Weighing Scale, Model
500 KL; Pelstar, Alsip, IL, USA). Following 15-minutes of
rest in a supine position, RHR and BP were assessed using
a digital blood pressure monitor (Omron Healthcare, Inc,
HEM-712C, Vernon Hills, Illinois, USA). A resting blood
sample was then obtained from an antecubital vein in the
superficial forearm using a 21-gauge disposable needle
stick by an experienced lab technician. Blood was drawn
into serum separator tubes (SST), serum tubes, and EDTA
tubes. SST and serum tubes were allowed to clot for
30 minutes prior to centrifugation and then separated at
3000 × g for 15 minutes at room temperature. The result-
ing serum from the serum tube was then transferred to a
5 mL transport tube. Samples were then packaged along
with a requisition form for analysis at a commercial la-
boratory (Quest Diagnostics, Tampa, FL, USA) for blood
lipids, metabolic blood chemistry, and complete blood
counts.
Supplement
The SUPP and PL were ingested in tablet form, and two
tablets were consumed per dose. Tablets were identical
in appearance and taste. The ingredients in SUPP are pre-
sented in Table 2, while the placebo consisted of only rice
powder. Participants were provided one dose per day ac-
cording to manufacturer recommendations. Supplementa-
tion began immediately following the blood draw at
pre- and ceased the day before post-testing. Partici-
pants did not ingest supplement or placebo on the day of
post-testing. Supplement administration was witnessed byresearch personnel during all weekdays. Additional work
in our laboratory showed elevated plasma caffeine and
theobromine concentrations for 8 hours following in-
gestion of Energize™ versus placebo, as determined via
high performance liquid chromatography (HPLC) [25].Statistical analyses
Statistical analysis of the data was accomplished using a
2 by 2 repeated measures analysis of variance (ANOVA)
to determine between groups differences (SUPP vs. PL).
In the event of significant differences between groups at
baseline, data from the corresponding pre-values were
used as a covariate in subsequent analysis. In the event of
a significant F-ratio, dependent t-tests were used for pair-
wise comparisons. A criterion α-level of p ≤ 0.05 was used
to determine statistical significance. Pre- and post- mean
values for all blood variables were compared against
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mean ± SD.
Results
Compliance among all participants was 98.3%. No signifi-
cant between-group differences were observed at baseline
for blood lipid variables, metabolic blood chemistry or
complete blood counts. Study participants reported no
adverse events during supplementation with either SUPP
or PL.
Heart rate and blood pressure measures
Pre- to post-supplementation changes for RHR and BP are
presented in Table 3. No significant differences between
the groups were observed for RHR, SBP or DBP (p = 0.945,
p = 0.327, and p = 0.678, respectively) from pre- to post-
supplementation.
Lipid panel
Pre- to post-supplementation changes in blood lipids are
presented in Table 4. No significant differences between
the groups were observed for total cholesterol (p = 0.523),
HDL cholesterol (p = 0.235), triglycerides (p = 0.752), LDL
cholesterol (p = 0.850), non-HDL cholesterol (p = 0.977)
or the cholesterol to HDL ratio (p = 0.861) from pre-to
post-supplementation. All values for all blood lipid mea-
sures remained within reference norms.
Metabolic blood chemistry
Pre- to post-supplementation changes in metabolic blood
chemistry are presented in Table 5. A significant difference
between groups was observed for plasma glucose concen-
trations (p = 0.028); however, follow-up testing revealed
that pre- to post-supplementation changes were not sig-
nificant for either SUPP (p = 0.077) or PL (p = 0.116). No
other changes in any blood chemistry variables were
noted. All values for the metabolic blood chemistry
measures remained within reference norms.
Complete blood counts
Pre- to post-supplementation changes in complete blood
counts are presented in Table 6. No significant differ-
ences between the groups were observed for any of the
cell count variables. Values for all blood count variables
remained within reference norms.Table 3 Changes in resting heart rate and blood pressure
Variable SUPP (n = 20)
Pre
Resting Heart Rate (bpm) 67.45 ± 16.70
Systolic Blood Pressure (mmHg) 123.25 ± 10.96
Diastolic Blood Pressure (mmHg) 70.10 ± 8.33
Pre = pre-supplementation; Post = post-supplementation; Data presented as mean ±Discussion
This is the first study to examine health and safety markers
following prolonged daily ingestion of a slow-release
energy supplement. The results of this study indicate
that daily ingestion of a slow-release energy supplement
containing approximately 200 mg · day−1 caffeine in com-
bination with other ingredients for 28 days does not sig-
nificantly affect blood lipids, metabolic blood chemistry
profiles or blood counts. In addition, no changes in resting
cardiovascular measures were noted, suggesting that pro-
longed use of the commercially available slow-release
energy supplement Energize™, is apparently safe in young
healthy adults.
Previous investigations have primarily focused on the
efficacy of ingesting a single, moderate dose of slow re-
lease caffeine (SRC) in sleep-deprived subjects [3,10,23].
Although a number of these studies have reported SRC
tolerability [21] and some have reported adverse events
[21,26], studies have been limited to the acute response
following a single 150–600 mg dose of SRC [3,20]. Lagarde
and colleagues [20] examined a number of cardiovascular
parameters including heart-rate, blood pressure and blood
chemistry prior to and following the acute ingestion of
150, 300 and 600 mg of SRC in healthy male and female
participants. Participants were subjected to 32-hours of
sleep-deprivation in a cross-over design with a 1-week
wash out period. During this time, participants underwent
regular clinical evaluations, while tolerance was evaluated
by complaints reported by the participants. Adverse events
were reported by 8 of the 24 participants (7 female, 1
male), which included numbness, shaking, muscular pains,
heart palpitations, and headaches. Two adverse events
were reported in the placebo group. No significant changes
in blood chemistry were observed; however, the authors
did not delineate the blood tests performed. Reports of
shivering and tachycardia were recorded in the 600 mg
group; however, a clear break-down of adverse events by
dosage was not presented. Additionally, it is not clear
whether the adverse effects were related to the SRC (at any
dosage), or due to the effects of sleep-deprivation.
Patat and colleagues [3] compared the effects of 600 mg
SRC to placebo in a number of psychomotor and cognitive
tasks in sleep-deprived subjects. Similar to our study, they
utilized routine laboratory tests including complete blood
counts and general blood chemistry in order to assess anyPL (n = 20)
Post Pre Post
64.40 ± 11.67 68.10 ± 9.40 64.85 ± 9.09
120.10 ± 11.06 122.25 ± 13.01 113.15 ± 26.95
68.65 ± 7.47 71.25 ± 7.85 68.95 ± 5.83
SD.
Table 4 Changes in blood lipids
Variable SUPP (n = 20) PL (n = 20) Reference Range
Pre Post Pre Post
Total Cholesterol (mg/dL) 163.5 ± 22.8 163.8 ± 24.1 155.5 ± 25.6 152.2 ± 25.2 125-170 mg/dL
HDL Cholesterol (mg/dL) 57.9 ± 12.3 60.4 ± 16.5 56.9 ± 16.0 55.9 ± 10.7 ≥ 40M, ≥ 46F mg/dL
Triglycerides (mg/dL) 71.0 ± 25.8 74.7 ± 30.6 70.5 ± 27.9 77.0 ± 37.6 38-152M, 40-136F mg/dL
LDL Cholesterol (mg/dL) 91.3 ± 25.0 88.5 ± 22.4 84.7 ± 21.1 81.0 ± 23.4 <130 mg/dL (calc)
Risk Ratio (CHOL/HDL) 3.0 ± 0.8 2.9 ± 0.7 2.9 ± 0.8 2.8 ± 0.8 ≤ 5.0 (calc)
Non-HDL cholesterol 105.6 ± 25.6 103.5 ± 23.5 98.7 ± 24.6 96.4 ± 28.2 n/a mg/dL (calc)
Pre = pre-supplementation; Post = post-supplementation; M = Male; F = Female; Data presented as mean ± SD.
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cardiovascular parameters. In line with our findings, they
observed no clinically relevant changes in routine labora-
tory tests and reported no safety related drop-out issues.
However, in contrast to our findings, three adverse events
were reported for the SRC group, including an episode of
anxiety in one subject, and one episode of trembling and
diarrhea in another. The observed differences between the
results of the present study, and those of Lagarde et al.
[20] and Petat et al. [3], is likely related to the differences
in the dosage used. By comparison, we used a relatively
moderate dose (approx. 200 mg SRC) compared to the
larger 600 mg dose utilized by others. Lagarde et al. [20]
suggest that the optimal dose, defined as the maximum ef-
fect without any side effects, is 300 mg of SRC.Table 5 Changes in blood chemistry
Variable SUPP (n = 20)
Pre Post
Glucose 88.3 ± 5.2 85.8 ± 6.1
Urea Nitrogen (BUN) 15.1 ± 4.2 15.4 ± 4.3
Creatinine 0.9 ± 0.2 1.0 ± 0.2
eGFR Non-Afr. American 107.3 ± 15.6 94.5 ± 15.8
eGFR Afr. American 124.4 ± 18.2 109.5 ± 18.2
Sodium 142.3 ± 2.9 143.2 ± 3.1
Potassium 4.6 ± 0.5 5.1 ± 0.5
Chloride 104.9 ± 2.6 105.7 ± 2.7
Carbon Dioxide 24.4 ± 2.7 25.4 ± 2.5
Calcium 9.6 ± 0.4 9.8 ± 0.3
Protein (TOTAL) 7.0 ± 0.4 7.1 ± 0.4
Albumin 4.5 ± 0.3 4.4 ± 0.3
Globulin 2.5 ± 0.4 2.6 ± 0.3
Albumin/Globulin Ratio 1.8 ± 0.4 1.7 ± 0.3
Bilirubin (TOTAL) 0.8 ± 0.5 0.7 ± 0.3
Alkaline Phosphatase 67.6 ± 17.2 65.4 ± 18.8
AST 25.9 ± 15.7 24.5 ± 12.0
ALT 21.4 ± 11.2 22.2 ± 13.3
‡ = Between groups interaction, p ≤ 0.05; Pre = pre-supplementation; Post = post-s
aminotransferase; ALT = alanine aminotransferase; M = Male; F = Female; Data preseConsidering that no adverse events were reported in the
present study, our results appear to support the conclu-
sions from Lagarde and colleagues [20]. Tolerability issues
reported in previous studies appear to be transient in na-
ture, with spontaneous remission occurring soon after the
symptoms present [3,20]. This did not appear to be a con-
cern in our study suggesting that tolerability in caffeine
users is not an issue at moderate doses of SRC.
Comparable results have been observed in other studies
investigating the safety aspects of similar multi-ingredient
energy/thermogenic supplements [27,28]. Following 28-
days ingestion of a popular multi-ingredient thermogenic
drink, Roberts and colleagues [28] reported no signifi-
cant group by time interactions for lipid profiles, complete
blood counts or general blood chemistry in a group ofPL (n = 20) Reference Range
Pre Post
83.2 ± 10.2 88.1 ± 6.24 ‡ 65-99 mg/dL
16.4 ± 4.1 16.4 ± 4.39 7-20 mg/dL
0.9 ± 0.2 1.0 ± 0.21 0.60-1.35M, 0.50-1.10F mg/dL
103.6 ± 18.2 95.8 ± 14.82 ≥ 60 mL/min/1.73 m2
119.9 ± 21.0 110.9 ± 17.19 ≥ 60 mL/min/1.73 m2
141.8 ± 3.2 143.1 ± 2.79 135-146 mmol/L
4.7 ± 0.4 4.9 ± 0.57 3.8-5.1 mmol/L
104.5 ± 2.2 104.9 ± 3.79 98-110 mmol/L
24.8 ± 2.0 26.1 ± 1.86 19-30 mmol/L
9.7 ± 0.4 9.7 ± 0.33 8.6-10.3M, 8.6-10.2F mg/dL
7.2 ± 0.5 7.0 ± 0.41 6.1-8.1 g/dL
4.5 ± 0.3 4.4 ± 0.28 3.6-5.1 g/dL
2.7 ± 0.3 2.6 ± 0.27 1.9-3.7 g/dL (calc)
1.7 ± 0.2 1.7 ± 0.19 1.0-2.5 (calc)
0.7 ± 0.4 0.7 ± 0.41 0.2-1.1 mg/dL
59.4 ± 21.4 57.0 ± 21.58 40-115M, 33-115F U/L
20.1 ± 8.8 20.0 ± 10.2 12-32 U/L
17.8 ± 7.9 18.8 ± 12.63 9-46M, 6-29F U/L
upplementation; eGFR = epidermal growth factor receptor; AST = aspartate
nted as mean ± SD.
Table 6 Changes in complete blood counts
Variable SUPP (n = 20) PL (n = 20) Reference Range
Pre Post Pre Post
WBC Count 6.0 ± 1.4 6.4 ± 1.7 6.1 ± 1.3 6.0 ± 1.5 4.5-13.0 Thousand/uL
RBC Count 4.6 ± 0.5 4.6 ± 0.6 4.7 ± 0.6 4.7 ± 0.6 4.10-5.70M, 3.80-5.10F Million/uL
Hemoglobin 13.7 ± 2.0 13.5 ± 2.1 13.8 ± 1.0 13.6 ± 1.5 12.0-16.9M, 11.5-15.3F g/dL
Hematocrit 39.7 ± 7.5 41.2 ± 5.7 41.6 ± 2.6 41.1 ± 4.1 36.0-49.0M, 34.0-46.0F%
MCV 89.0 ± 5.5 89.0 ± 5.8 88.8 ± 6.8 89.1 ± 6.9 78.0-98.0 fL
MCH 29.5 ± 2.6 29.3 ± 2.4 29.5 ± 2.7 29.5 ± 2.7 25.0-35.0 pg
MCHC 33.1 ± 1.3 32.8 ± 0.9 33.2 ± 1.0 33.1 ± 0.9 31.0-36.0 g/dL
RDW 14.1 ± 1.5 14.1 ± 1.3 13.7 ± 1.0 13.9 ± 0.9 11.0-16.0%
Platelet Count 215.5 ± 47.3 222.8 ± 54.6 207.3 ± 45.9 207.6 ± 47.1 150-400 Thousand/uL
Abs Neutrophils 3403.9 ± 1131.6 3790.1 ± 1660.3 3289.9 ± 1194.9 3482.3 ± 1198.5 1800-8000 cells/uL
Abs Lymphocytes 1947.6 ± 471.3 1934.3 ± 570.4 2006.3 ± 640.6 1954.7 ± 533.1 1200-5200 cells/uL
Abs Monocytes 428.9 ± 122.0 419.2 ± 124.2 414.3 ± 109.0 388.0 ± 118.4 200-900 cells/uL
Abs Eosinophils 179.6 ± 122.2 213.0 ± 268.7 124.4 ± 98.6 131.5 ± 105.4 15-600 cells/uL
Abs Basophils 30.2 ± 19.9 28.7 ± 15.1 25.4 ± 12.5 23.8 ± 7.9 0-250 cells/uL
Neutrophils 56.0 ± 7.4 57.8 ± 11.5 57.6 ± 6.7 57.4 ± 7.4 %
Lymphocytes 33.0 ± 6.5 31.6 ± 9.8 33.1 ± 6.9 33.3 ± 7.4 %
Monocytes 7.2 ± 1.5 6.7 ± 1.5 6.9 ± 1.6 6.7 ± 1.9 %
Eosinophils 3.2 ± 2.4 3.4 ± 4.4 2.0 ± 1.4 2.2 ± 1.8 %
Basophils 0.5 ± 0.4 0.5 ± 0.4 0.4 ± 0.2 0.4 ± 0.2 %
Pre = pre-supplementation; Post = post-supplementation; WBC = white blood cell; RBC = red blood cell; MCV = mean corpuscular volume; MCH = mean
corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; RDW = red blood cell distribution width; Abs = absolute; M = Male; F = Female;
Data presented as mean ± SD.
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were reported in resting cardiovascular measures (RHR,
SBP and DBP). Similarly, Lockwood and colleagues [27]
observed no significant changes in clinical safety markers
following 10-weeks of daily supplementation with a low-
calorie multi-ingredient energy drink. Both of these stud-
ies utilized supplements that contained similar amounts of
caffeine (approx. 200 mg) along with other ingredients.
The safety data in the present study appears to be consist-
ent with that of similar energy blend supplements deliv-
ered in a non-time-released manner.
Conclusions
In summary, this appears to be the first investigation on
the health and safety aspects of prolonged ingestion of a
commercially available slow-release energy supplement.
A 28-day ingestion protocol resulted in no changes in lipid
profile, blood chemistry, blood counts and resting cardio-
vascular measures, and all measures remained within
normal, established reference ranges for adults. These find-
ings indicate that 28 consecutive days ingestion of a mod-
erate amount of caffeine, as part of a multi-ingredient
time-release supplement, in caffeine users is both safe
and tolerable. This may have important relevance inprofessions, where continuous operations demand peak
cognitive and physical performance for sustained periods
of time.
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